AB040. SOH26AB_0089. Quality-of-life outcomes in human epidermal growth factor receptor-2-positive breast cancer: a systematic review and meta-analysis of randomised clinical trials

Targeted therapies have significantly reshaped the treatment of human epidermal growth factor receptor-2-positive (HER2⁺) breast cancer. In parallel with advances in survival, randomised controlled trials (RCTs) have increasingly incorporated patient-reported outcome measures (PROMs) to evaluate quality-of-life (QoL) effects. This review aimed to examine how PROMs and QoL assessments are implemented in RCTs of targeted therapies for HER2⁺ breast cancer and to explore whether improvements in overall survival (OS) and progression-free survival (PFS) correspond with preserved QoL.